Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-268019 versus COMIRNATY in adolescents for COVID-19 prevention
jRCT2031220063Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268019 arm with COMIRNATY arm (2 arms). Primary endpoints: SARS-CoV-2 neutralizing antibody titer after priming vaccination and SARS-CoV-2 neutralizing antibody titer after booster vaccination. Started May 2022; status: completed.
02
Drugs
S-268019-btozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220063.